The Elecsys Anti-TSHR immunoassay is a three-step competitive immunoassay with streptavidin-coate...

FDA Recall #Z-1009-2026 — Class II — November 21, 2025

Recall #Z-1009-2026 Date: November 21, 2025 Classification: Class II Status: Ongoing

Product Description

The Elecsys Anti-TSHR immunoassay is a three-step competitive immunoassay with streptavidin-coated microparticles and electrochemiluminescence detection. Patient serum sample is incubated with pretreatment reagent PT1 and the reconstituted PT2 containing a pre-formed immunocomplex of solubilized porcine TSH receptor (pTSHR) and biotinylated anti-pTSHR mouse monoclonal antibody.

Reason for Recall

Issues identified: 1) Results vary by Instrument Platform; 2) Calibrator Lot-to-Lot Variability. Issues may lead to delayed or incorrect diagnosis, as well as delay of treatment or incorrect treatment.

Recalling Firm

Roche Diagnostics Operations, Inc. — Indianapolis, IN

Classification

Class II — May cause temporary or medically reversible adverse health consequences.

Product Type

Devices

Product Quantity

1300 cassettes

Distribution

US Nationwide distribution in the states of AZ, CA, FL, GA, IL, IN, ME, MI, MN, NC, NJ, NM, NY, OH, PA, PR, TN, TX, UT, WA, WV.

Code Information

08496633190 lot 840183 exp. 02/26 08496633190 lot 874011 exp. 10/26 08496609190 lot 840177 exp. 05/26

Status

Ongoing

Voluntary / Mandated

Voluntary: Firm initiated